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Fatigue in cancer patients is highly
prevalent, predominantly idiopathic,
difficult to manage, and has a significant
negative impact on quality of life.
Thyrotropin-releasing hormone (TRH)
exerts normotrophic, state-dependent
therapeutic effects in a variety of
experimental and clinical situations. To
evaluate TRH as a treatment for cancer-
related fatigue, an ongoing randomized,
placebo-controlled, crossover pilot study of
breast cancer patients has been initiated
and this report presents preliminary
observations conducted with three of these
patients over 4 consecutive weeks, thereby
involving a total of six TRH treatments and
six saline controls. Global assessment using
both subjective and objective parameters
showed that TRH exerted clear anti-fatigue
effects in four of the six TRH treatments.
These responses were rapid in onset and
persisted through the 24 h observation
period. No anti-fatigue responses were seen
in five of the six saline controls. No
unexpected side-effects were seen with TRH
administration. These initial findings
support the proposal that TRH can
ameliorate cancer-related fatigue.
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Introduction
Fatigue is the most common symptom of
cancer and cancer treatments.1 It is
exceedingly debilitating and may persist for
months or even years after completion of
treatment.2 Frequently accompanied by
comorbidities, such as depression or pain,
cancer-related fatigue is sometimes
associated with underlying contributory
factors such as anemia, electrolyte
abnormalities or hypothyroidism.3 In most
patients, however, specific causative factors
cannot be identified. This idiopathic fatigue
is often profound, persistent and invariably
unrelieved by rest.4 To date, no therapeutic
intervention has been shown to be reliably
effective.5
Cancer-related fatigue can be viewed as a
failure of homeostasis. It has been associated
with a cascade of interrelated changes in the
neuroendocrine system, central/peripheral
nervous system, neurotransmitter
metabolism and circadian rhythms.6,7
Additionally, existing evidence suggests that
1153
J Kamath, GG Yarbrough, AJ Prange Jr et al.
Relief of cancer-related fatigue with TRH
fatigue in cancer patients is associated with
immune dysfunction and may be due to the
actions of various pro-inflammatory
cytokines released as a result of the disease
process as well as in response to radiation
and/or chemotherapeutic treatment
interventions.8
As first proposed in 2003, thyrotropin-
releasing hormone (TRH; pGlu–His–ProNH2)
is thought to be widely involved in the
control of behavioral, metabolic and
immunological homeostasis.9 – 11 This
teleologically-based understanding of the
fundamental role of TRH is consonant with
its ubiquitous distribution and its
involvement in many physiological
processes, above and beyond its
neuroendocrine functions.9 Moreover, this
unifying hypothesis provides insight into the
basis of the widely reported, diverse and non-
disease-specific therapeutic effects of TRH
and TRH-mimetic analogs.10 Thus, in
various clinical situations and disease states
TRH agonism exerts normotrophic, state-
dependent therapeutic effects which
manifest as restorations of homeostasis,
including that of the immune system.11 In
instances of behavioral depression, TRH
agonism exerts arousing and analeptic
actions. Additionally, TRH can counteract
various immune dysfunctions known to be
associated with cancer-related fatigue.11
In light of the above considerations, it was
hypothesized that TRH agonism should
ameliorate cancer-related fatigue.11 To assess
this possibility, a pilot trial has been set up to




Informed consent was obtained in writing
from each participant. Patients with breast
cancer who were experiencing cancer-related
fatigue according to the criteria of the
International Classification of Diseases 10th
Revision (ICD-10)12,13 were eligible for
inclusion in the study. Patients were also
required to have a score of < 34 on the
Functional Assessment of Cancer Therapy
(FACT)–Fatigue scale14 at the initial
evaluation. Patients with clearly identifiable
but untreated causes of fatigue (e.g. anemia)
were excluded, as were patients with any
unstable and clinically significant
psychiatric or substance use disorders, and
those with a history of cardiovascular
disease. Patients with comorbidities (e.g.
depression, insomnia) were included if the
comorbid factors were not judged to be the
main causative factors of fatigue.
STUDY DESIGN
This pilot phase II trial employed a double-
blind, placebo-controlled, crossover design
with two randomizations (www.Clinical
Trials.gov identifier NCT00790296). Patients
were assessed for fatigue 1 h before and 3, 7,
and 24 h after intravenous administration of
TRH (either 0.5 or 1.5 mg) or saline placebo.
This procedure was performed once weekly
over 4 consecutive weeks, resulting in a total
of six TRH treatments and six controls (Fig. 1).
The primary outcome measure was the
visual analog scale for energy level (VAS-E)14
as assessed by the subject. Other outcome
measures included the multidimensional
fatigue inventory,15 functional assessment
using a 6-min walk test16 and a quality of life
assessment using the FACT–General
questionnaire.17 Comorbid factors were
evaluated using the modified, four-item
Leeds Sleep Evaluation Questionnaire,18 the
Hospital Anxiety and Depression
questionnaire19 and the 65-item Profile of
Mood States questionnaire.20 A blinded
clinician rated fatigue status and general
quality of life using the Clinical Global
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Impression (CGI) scale before and after
administration of study medication.
The study protocol was approved by the
University of Connecticut Health Center
Institutional Review Board. All study
procedures were conducted in accordance
with an Investigational New Drug
application (IND 72,351) approved by the
Food and Drug Administration of the USA.
Results
To date, three patients have each received
two injections of saline and two injections of
TRH (0.5 and 1.5 mg) in accordance with the
crossover study treatment schedule, giving a
total of six TRH treatments and six controls.
All three patients were in remission and had
completed cancer treatments at least 2 years
(range 2 – 5 years) before the study. No
clinically relevant medical or psychiatric
comorbidities were noted in any of the
patients.
Data on the overall positive (+) anti-
fatigue or negative (−) no anti-fatigue
responses to each of the six TRH treatments
and six controls are presented in Table 1.
This shows the combined assessments of the
subjective primary outcome measure (VAS-E
score) plus the objective walking test results
and observations by an observer blinded to
the treatments and represent our qualitative
global assessments of each patient’s response
to each treatment. The change in VAS-E
scores at 3, 7, and 24 h show that the anti-
fatigue related effects of TRH remained
evident through the 24 h observation period
after dosing (Table 1).
In four of the six TRH treatments, clear
anti-fatigue responses were seen. These
responses became evident 3 – 7 h after
dosing, persisted through the 24 h
observation period and were reported as
considerable and robust by the patients.
Possible dose–response effects of TRH were
not evident in these limited data. In patient
II with treatment 3 (week 3), no response to
TRH was seen, however, at that time the
patient was not clearly fatigued, which
conceivably might be ascribed to a carry-
over effect from the TRH treatment received a
FIGURE 1: Schematic of the double-blind, placebo-controlled, crossover study design
with two randomizations that was employed to assess the effect of thyrotropin-
releasing hormone (TRH) on cancer-related fatigue (CrF) in breast cancer patients
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week earlier. In patient III with treatment 1
(week 1), only a tendency (+/–) towards
improvement was discerned after
administration of 0.5 mg TRH. Transient,
modest increases in blood pressure and heart
rate were the main (and expected) side-
effects21 after TRH administration. No
unexpected side-effects were noted.
Among the six placebo infusion trials, a
clear anti-fatigue response was noted only in
patient III with treatment 2 (week 2). For
another placebo infusion trial, no clear
conclusions could be adduced from patient II
with treatment 4 (week 4). Saline injections
produced no anti-fatigue effects in the other
four placebo infusion trials.
Discussion
Despite the widely documented high
prevalence of cancer-related fatigue and its
impact on quality of life, effective
interventions for this debilitating condition
remain elusive.4 Evidence for non-
pharmacological relief of cancer-related
Treatment/Week
Patient/Assessment 1 2 3 4
Patient I TRH 0.5 mg Salinea TRH 1.5 mg Salinea
Change in VAS-Ec
3 h +/– – +/– –
7 h + – + –
24 h + – + –
Globald + − + −
Patient II Saline TRH 0.5 mg TRH 1.5 mgb Saline
Change in VAS-Ec
3 h – +/– – –
7 h – + – –
24 h +/– + – +
Globald − + − +/−
Patient III TRH 0.5 mg Saline Saline TRH 1.5 mg
Change in VAS-Ec
3 h + + – +
7 h + + – +
24 h + + – +
Globald +/− + – +
aModest increase in fatigue noted.
bIn this patient no fatigue was evident in week 3 at baseline perhaps as a consequence of previous TRH
exposure at week 2.
cChange in VAS-E was calculated by comparing scores to baseline (1 h prior to study medication
administration) and was considered a positive anti-fatigue response (+) if the change in VAS-E score was
≥25% compared with baseline; –, no change from baseline; +/–, <25% change from baseline.
dGlobal assessment of the response represents the combined assessments of the subjective visual analog scale
for energy level (VAS-E) scores 3, 7, and 24 h after treatment compared with the 1 h pre-treatment baseline
and patient comments plus the objective walk test results and the observations of an observer blinded to the
treatments: +, overall positive anti-fatigue response, including ≥ 25% increase in VAS-E score compared with
baseline; –, no anti-fatigue response; +/–, equivocal, unclear response, including slight increase in VAS-E score.
TABLE 1:
Changes in visual analog scale for energy (VAS-E) scores at 3 , 7, and 24 h and global
assessment of the effect of thyrotropin-releasing hormone (TRH) or saline control on
cancer-related fatigue in three breast cancer patients
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